Skip to main content
Publications
Keens T, Hoffman V , Topuria I, Elder K, Cerf S, Mulder K, Roberts J, Lysinger J, Del Carmen Reyes M, Berdella M, Cairns AM, Jain M, Ganapathy V, Lou Y, Morcos B, Wu C, Sass L, VX19-CFD-003 Study Group. Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis . Heliyon. 2024 Mar 26;10(7):e28508. doi: 10.1016/j.heliyon.2024.e28508
Duran CE, Riera-Arnau J, Abtahi S, Pajouheshnia R , Hoxhaj V, Gamba M, Alsina E, Martin-Perez M, Garcia-Posa P, Llorente-Garcia A, Gonzalez-Bermejo D, Ibanez L, Sabate M, Vidal X, Ballarin E, Sanfelix-Gimeno G, Rodriguez-Bernal C, Peiro S, Garcia-Sempere A, Sanchez-Saez F, Lentile V, Ingrasciotta Y, Guarneri C, Tanaglia M, Tari M, Herings R, Houben E, Swart-Polinder K, Holthuis E, Huerta C, Gini R, Roberto G, Bartolini C, Paoletti O, Limoncella G, Girardi A, Hyeraci G, Andersen M, Kristiansen SB, Hallgreen CE, Klungel O, Sturkenboom M. Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis . Front Pharmacol. 2023 Aug 17;14:1207976. doi: 10.3389/fphar.2023.1207976
Abdulkareem NM, Bhat R, Powell RT, Chikermane S, Yande S , Trinh L, Abdelnasser HY, Tabassum M, Ruiz A, Sobieski M, Nguyen ND, Johnson M, Kaipparettu BA, Johnson CA, Bond RA, Stephan C, Triveni MV. Screening of GPCR drugs for repurposing in breast cancer . Front Pharmacol. 2022 Dec 6;13:1049640. doi: 10.3389/fphar.2022.1049640